Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Symphogen A/S

Overview

This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Metastatic Colorectal Cancer

Interventions

Sym004DRUG

Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion and Exclusion criteria have been removed due to Symphogen's business decision to no longer perform the clinical study.

Outcomes

Primary Outcomes

Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.